Moleculin Biotech (MBRX) Gains from Investment Securities (2017 - 2026)
Moleculin Biotech (MBRX) posted quarterly Gains from Investment Securities of -$23.4 million for Q4 2025, down 1371.4% quarter-over-quarter from -$1.6 million in Q3 2025.
Moleculin Biotech (MBRX) Gains from Investment Securities (2017 - 2026) Analysis & Trends
Moleculin Biotech's Gains from Investment Securities history runs 8 years deep, the most recent figure standing at -$23.4 million for Q4 2025.
- In Q4 2025, Gains from Investment Securities changed N/A year-over-year to -$23.4 million; the TTM figure through Dec 2025 stood at -$24.4 million (changed N/A YoY), while the FY2025 annual figure was -$24.4 million, changed N/A from the prior year.
- Gains from Investment Securities for Q4 2025 stood at -$23.4 million, down from -$1.6 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $1.1 million in Q4 2023, with the low at -$23.4 million in Q4 2025.
- The 4-year median for Gains from Investment Securities is -$421000.0 (2022), against an average of -$2.1 million.
- The sharpest annual moves came in 2021 and 2023: Gains from Investment Securities slumped 168.38% in 2021, then jumped 841.72% in 2023.
- Moleculin Biotech's Gains from Investment Securities stood at -$2.3 million in 2021, then soared by 93.43% to -$151000.0 in 2022, then surged by 841.72% to $1.1 million in 2023, then sank by 2190.18% to -$23.4 million in 2025.
- Business Quant data shows MBRX's Gains from Investment Securities at -$23.4 million in Q4 2025, -$1.6 million in Q3 2025, and $560000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7,000.00 |
| Jun 30, 2026 | 7,000.00 |
| Dec 31, 2025 | -23.41 Mn |
| Dec 31, 2025 | -23.41 Mn |
| Sep 30, 2025 | -1.59 Mn |
| Sep 30, 2025 | -1.59 Mn |
| Jun 30, 2025 | 560,000.00 |
| Jun 30, 2025 | 560,000.00 |
| Dec 31, 2023 | 1.12 Mn |
| Dec 31, 2023 | 1.12 Mn |
| Sep 30, 2023 | -1,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -36,000.00 |
| Jun 30, 2023 | -36,000.00 |
| Mar 31, 2023 | -39,000.00 |
| Mar 31, 2023 | -39,000.00 |
| Dec 31, 2022 | -151,000.00 |
| Dec 31, 2022 | -151,000.00 |
| Sep 30, 2022 | -421,000.00 |
| Sep 30, 2022 | -421,000.00 |